European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.
You may also be interested in...
Biogen Idec get nod after providing more data, but restrictions imposed mean Tecfidera is unlikely to leap ahead of a packed field.
NICE has demanded more data and analyses for Biogen Idec’s MS champion, Tecfidera, before it clears a drug expected to be a worthy opponent for Novartis’ Gilenya.
All too often, pharmaceutical companies and investors put up hurdles, but they can and must identify indications and assets with high future market access potential in early stages by adjusting the early screening and evaluation process.